The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer

Sponsor
Junling Li
Study ID
NCT03129698
Phase
PHASE2
Status
Unknown

Conditions

  • Apatinib in Maintenance Treatment

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

52 patients with extensive-stage small-cell lung cancer and without progression after completing chemotherapy, will receive apatinib monotherapy as maintenance therapy.

Key Dates

Start date
Apr 11, 2017
Status verified
Apr 2017
Primary completion
Mar 1, 2019
Completion
Mar 1, 2020

Study Design

Enrollment
52 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Formerly Arm Label
    Apatinib 250mg daily

Primary Outcome Measure

progression-free survival [ Time Frame: 6 months ]

Central Contacts